Tatarewicz and colleagues demonstrated that the presence of very small amounts (0.55%) of high molecular aggregates in the preparations of ruthenylated monoclonal antibody used in a bridging electrochemiluminescent immunogenicity assay caused a significant increase of baseline ADA responses in subjects with rheumatoid arthritis. This evidence concerns the gene ADA and rheumatoid arthritis.